Induced pluripotent stem cells in modeling and cell-based therapy of amyotrophic lateral sclerosis

• Published in: Journal of physiology and pharmacology : an official journal of the Polish Physiological Society Vol. 68; no. 5; p. 649
• Main Authors: Csobonyeiova, M, Polak, S, Nicodemou, A, Danisovic, L
• Format: Journal Article
• Language: English
• Published: Poland 01.10.2017
• ISSN: 1899-1505

Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease characterized by neuromuscular degeneration and the progressive loss of upper and lower motor neurons (MNs), causing weakness and paralysis. However, the underlying mechanisms of this disease are still unknown and there is no cure, or even treatment to stop or reverse its pathology. Consequently, most ALS patients die within 3 - 5 years after disease onset. While considerable progress has been made in studying animal models of ALS, they lack clinical suitability due to genetic differences. However, the recent development of induced pluripotent stem cells (iPSCs) has made it possible to study human disease-specific neuronal and glial cells to identify disease mechanisms and develop phenotypic screens for drug discovery. iPSCs provide researchers with a model of naturally occurring pathology under the human genetic background and MNs differentiated from human iPSCs bearing ALS-associated mutations offer a powerful model to study disease pathology. This paper reviews recent methods of differentiating iPSCs into neuronal cells and suggests further applications of these iPSCs-derived cells for ALS disease modeling, drug screening, and possible cell-based therapy.